F-group (family)
101.1.2.9 DNA_topoisoIV
Ligands and drugs
713
Member domains
261
with ligand contacts (≤ 4 Å)
36.6% of members
203
with DrugDomain annotations
28.5% of members
110
with a DrugBank compound
15.4% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 101.1.2.9 belongs to X-group 101 HTH, which binds 8.7 ligand superclasses per 20 proteins, broader than 73% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00218 | MFX | Moxifloxacin | 17 |
| DB00773 | EVP | Etoposide | 16 |
| DB01137 | LFX | Levofloxacin | 15 |
| DB12134 | JHN | Gepotidacin | 10 |
| DB00685 | TR6 | Trovafloxacin | 7 |
| DB15345 | 6EJ | GSK-945237 | 6 |
| DB00537 | CPF | Ciprofloxacin | 5 |
| DB00276 | ASW | Amsacrine | 3 |
| DB08651 | TSP | 3'-THIO-THYMIDINE-5'-PHOSPHATE | 3 |
| DB00380 | — | Dexrazoxane | 2 |
| DB00694 | — | Daunorubicin | 2 |
| DB00997 | — | Doxorubicin | 2 |
| DB01204 | MIX | Mitoxantrone | 2 |
| DB01643 | DT | Thymidine monophosphate | 2 |
| DB05022 | — | — | 2 |
| DB06362 | — | — | 2 |
| DB06421 | — | — | 2 |
| DB12817 | R8U | Zoliflodacin | 2 |
| DB00385 | — | — | 1 |
| DB00444 | — | Teniposide | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| MGmetal | MAGNESIUM ION | 48 |
| EVP | (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside | 25 |
| MFX | 1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 18 |
| LFX | (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid | 15 |
| JHN | (3~{R})-3-[[4-(3,4-dihydro-2~{H}-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.0^{4,12}]dodeca-6,8(12),9-triene-5,11-dione | 12 |
| JK8 | (2~{R})-2-[[5-(2-chlorophenyl)-1,2-benzoxazol-3-yl]oxy]-2-phenyl-ethanamine | 9 |
| MNmetal | MANGANESE (II) ION | 8 |
| TE9 | delafloxacin | 8 |
| CPF | 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID | 7 |
| 6EJ | (1R)-1-[(4-{[(6,7-dihydro[1,4]dioxino[2,3-c]pyridazin-3-yl)methyl]amino}piperidin-1-yl)methyl]-9-fluoro-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one | 6 |
| CL | CHLORIDE ION | 6 |
| Kmetal | POTASSIUM ION | 6 |
| PDQ | 3-amino-7-{(3R)-3-[(1S)-1-aminoethyl]pyrrolidin-1-yl}-1-cyclopropyl-6-fluoro-8-methylquinazoline-2,4(1H,3H)-dione | 6 |
| RXV | 6-METHOXY-4-(2-{4-[([1,3]OXATHIOLO[5,4-C]PYRIDIN-6-YLMETHYL)AMINO]PIPERIDIN-1-YL}ETHYL)QUINOLINE-3-CARBONITRILE | 6 |
| TR6 | Trovafloxacin | 6 |
| 53M | (2R,4S,4aS)-4',6'-dihydroxy-2,4-dimethyl-8-nitro-1,2,4,4a-tetrahydro-2'H,6H-spiro[1,4-oxazino[4,3-a]quinoline-5,5'-pyrimidin]-2'-one | 4 |
| 8MX | 1-cyclopropyl-6-fluoro-8-methyl-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 4 |
| 94H | ~{N}-[(1~{R})-2-azanyl-1-phenyl-ethyl]-4-(1~{H}-pyrrolo[2,3-b]pyridin-3-yl)thiophene-2-carboxamide | 4 |
| A1L5V | 6-[(5S)-5-[[[2-(7-Fluoro-1,2-dihydro-1-methyl-2-oxo-8-quinolinyl)ethyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2H-pyrazino[2,3-b]-1,4-oxazin-3(4H)-one | 4 |
| E32 | 7-[(3~{S})-3-azanylpyrrolidin-1-yl]-5-cyclopropyl-8-fluoranyl-imidazo[1,2-a]quinoxalin-4-one | 4 |